Mesothelioma Cancer Centers
University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center
Doctors Affiliated with this Treatment Facility
While the Greenebaum Cancer Center received its National Cancer Institute designation in 2008, its involvement with the government institute began much earlier. In 1965, the early days of chemotherapy, the NCI founded an intramural program in the Division of Cancer Treatment located at the U.S. Public Health Service Hospital in Baltimore. The 40-bed program was created as a home for NCI research activities, and was called the Baltimore Cancer Research Center of the NCI. Many important studies were conducted there in an effort to find a cure for the disease.
In 1976, the Baltimore Cancer Research Center was relocated to the University of Maryland School of Medicine, and in 1978 it was renamed the Baltimore Cancer Research Program. The program separated from the federal government in 1981 and became the University of Maryland Cancer Center. In 1996, the center was renamed again, this time to the University of Maryland Greenebaum Cancer Center. The name is a nod to Marlene Greenebaum, a breast cancer survivor, and her husband Stewart, who had donated $10 million to the cancer hospital.
The Greenebaum Cancer Center offers a range of top-of-the-line technology designed to detect and treat cancer, which has led to the center receiving the highest ranking in the technology category from U.S. News & World Report, as well as a survival rate of “much better than expected.” The University of Maryland Medical Center offers treatment for pleural mesothelioma at their Mesothelioma and Thoracic Oncology Treatment and Research Center. The center is one of few in the world with several highly experienced mesothelioma experts on staff. They take a multidisciplinary approach to treating pleural mesothelioma to find the best treatment solutions for patients.
The experts at the University of Maryland Medical Center combine their expertise in surgery, radiation therapy, pulmonary and integrative medicine, pathology and palliative care to deliver customized treatment plans. The center also offers clinical trials for pleural and peritoneal mesothelioma. Although not all patients are suited for clinical trials, the team will help to determine if the opportunity is right for the patient.
The Mesothelioma and Thoracic Oncology Treatment and Research Center also offers a mesothelioma nurse who coordinates appointments with doctors in different areas of expertise, as well as communicates with patients’ health insurance providers to create an easy and convenient experience amidst the complex treatment that is required for mesothelioma patients. The Greenebaum Cancer Center also offers a staff of social workers and psychologists who are experienced with the special needs of cancer patients and their families. Social workers may also put newly diagnosed patients in touch with other patients who have gone through a similar type of cancer and treatment. This bond can help make the process less stressful by allowing patients to learn from others who have been through the process before.
- Radiation therapy
- Surgery (extended pleurectomy-decortication)
- Tri-modality therapy
- Proton therapy
- Commission on Cancer (CoC) accreditation
- National Cancer Institute (NCI) Comprehensive Care Center
- Ranked Top 50 National Best Hospitals for Cancer by U.S. News & World Report
Mesothelioma Clinical Trials at University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center
The following clinical trials are in progress or actively recruiting participants at University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center:
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm Last Updated: June 10, 2019 Status: Recruiting
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma Last Updated: May 17, 2019 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
University of Maryland Marlene and Stewart Greenebaum Cancer Center. Mesothelioma.